VIDEO: Simplified screening, treatment strategies critical in HBV

ByPaul Kwo, MD

ByMarley V. Ghizzone

Fact checked byKatrina Altersitz

PHILADELPHIA — Paul Kwo, MD, professor of medicine at Stanford University, speaks with Healio about presentations investigating the undertreatment of hepatitis B.

The data was presented at the ACG Annual Scientific Meeting.

According to Kwo, the oral presentation highlighted discrepancies in treatment for hepatitis B and the lack of clarity in which guidelines physicians follow when implementing treatment.

“This presentation showed that as you simplify the strategies for hepatitis B, this hopefully will allow us to identify more people who are eligible for treatment,” he said.

Reference

Wong R, et al. Monitoring Gaps and Treatment Disparities Among Adults With Chronic Hepatitis B Infection in the United States: Role of Treatment Eligibility Criteria. Presented at: ACG Annual Scientific Meeting; Oct. 25- 30, 2024; Philadelphia (hybrid meeting).

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Kwo reports serving as an advisor or review Panel Member for AbbVie; an advisory committee or board member for Aligos, Drug Farm, Gilead and Inventiva; receiving grant or research support from Altimmune, Fractyl, Gilead, Inventiva, Madrigal, Novo Nordisk, Target Registries and Ultragenyx; serving as a consultant for Durect, HepQuant, PPD and Surrozen; and owning stock options in Durect.

Discoveries in Liver

Read more

VIDEO: Simplified screening, treatment strategies critical in HBV

Reference

Related Content